The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
Open accessAbstract
// Su Yin Lim 1 , Arseniy E. Yuzhalin 1 , Alex N. Gordon-Weeks 1 and Ruth J. Muschel 1 1 CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom Correspondence to: Su Yin Lim, email: // Keywords : chemokines, cancer metastasis, cancer therapy, clinical trials Received : October 26, 2015 Accepted : January 31, 2016 Published : February 14, 2016 Abstract The CCL2-CCR2 signaling axis has generated increasing interest in recent years due to its association with the progression of cancer. Although first described as a chemotactic molecule with physiological roles in regulating inflammation, recent studies have revealed a pro-tumorigenic function for CCL2 in favoring cancer development and subsequent metastasis. CCL2 binds the cognate receptor CCR2, and together this signaling pair has been shown to have multiple pro-tumorigenic roles, from mediating tumor growth and angiogenesis to recruiting and usurping host stromal cells to support tumor progression. The importance of CCL2-CCR2 signaling has been further championed by the establishment of clinical trials targeting this signaling pair in solid and metastatic cancers. Here we review the roles of CCL2-CCR2 signaling in the development and progression of cancer metastasis. We further evaluate the outcome of several clinical trials targeting either CCL2 or CCR2, and discuss the prospects and challenges of manipulating CCL2-CCR2 interaction as a potential approach for combating metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedThe PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Monocyte recruitment during infection and inflammation
Shi, C., & Pamer, E. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3070 · Cited by 3,015
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
The Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Bonecchi, R., Bianchi, G., Bordignon, P. P., D'Ambrosio, D., Lang, R., Borsatti, A., Sozzani, S., Allavena, P., Gray, P. A., Mantovani, A., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.1.129 · Cited by 2,014
Rollins, B. J. (1997) · Blood · doi:10.1182/blood.v90.3.909 · Cited by 1,984
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Models, mechanisms and clinical evidence for cancer dormancy
Aguirre-Ghiso, J. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2256 · Cited by 1,677
Dissecting the metastatic cascade
Pantel, K., & Brakenhoff, R. H. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1370 · Cited by 1,281
Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese, R. V., Broxmeyer, H. E., & Charo, I. F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119798 · Cited by 1,096
Direct Visualization of Macrophage-Assisted Tumor Cell Intravasation in Mammary Tumors
Wyckoff, J. B., Wang, Y., Lin, E. Y., Li, J.-F., Goswami, S., Stanley, E. R., Segall, J. E., Pollard, J. W., & Condeelis, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1823 · Cited by 1,053
Lu, B., Rutledge, B. J., Gu, L., Fiorillo, J., Lukacs, N. W., Kunkel, S. L., North, R., Gerard, C., & Rollins, B. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.601 · Cited by 1,017
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Salcedo, R., Ponce, M. L., Young, H. A., Wasserman, K., Ward, J. M., Kleinman, H. K., Oppenheim, J. J., & Murphy, W. J. (2000) · Blood · doi:10.1182/blood.v96.1.34 · Cited by 859
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1
Gu, L., Tseng, S., Horner, R. M., Tam, C., Loda, M., & Rollins, B. J. (2000) · Nature · doi:10.1038/35006097 · Cited by 832
Chemokines as regulators of T cell differentiation
Luther, S. A., & Cyster, J. G. (2001) · Nature Immunology · doi:10.1038/84205 · Cited by 736
(2000) · PubMed · Cited by 706
Charo, I. F., Myers, S. J., Herman, A., Franci, C., Connolly, A. J., & Coughlin, S. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2752 · Cited by 705
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M.-M., Wyckoff, J., Mertz, K. D., Varga, Z., Junt, T., & Bentires-Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 665
Qian, B., Deng, Y., Im, J. H., Muschel, R. J., Zou, Y., Li, J., Lang, R. A., & Pollard, J. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006562 · Cited by 664
Self-citationKitamura, T., Qian, B.-Z., Soong, D., Cassetta, L., Noy, R., Sugano, G., Kato, Y., Li, J., & Pollard, J. W. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141836 · Cited by 651
Chemokines and chemokine receptors: new insights into cancer-related inflammation
Lazennec, G., & Richmond, A. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.003 · Cited by 650
Schmidt-Kittler, O., Ragg, T., Daskalakis, A., Granzow, M., Ahr, A., Blankenstein, T. J. F., Kaufmann, M., Diebold, J., Arnholdt, H., Müller, P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1331931100 · Cited by 631
Sanford, D. E., Belt, B. A., Panni, R. Z., Mayer, A., Deshpande, A. D., Carpenter, D., Mitchem, J. B., Plambeck-Suess, S. M., Worley, L. A., Goetz, B. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0525 · Cited by 613
The chemokine and chemokine receptor superfamilies and their molecular evolution.
Zlotnik, A., Yoshie, O., & Nomiyama, H. (2006) · Genome biology · doi:10.1186/gb-2006-7-12-243 · Cited by 604
Rollins, B. J. (1997) · PubMed · Cited by 603
The inflammatory chemokines CCL2 and CCL5 in breast cancer
Soria, G., & Ben-Baruch, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.018 · Cited by 593
Mechanisms Governing Metastatic Dormancy and Reactivation
Giancotti, F. G. (2013) · Cell · doi:10.1016/j.cell.2013.10.029 · Cited by 586
Roca, H., Varsos, Z. S., Sud, S., Craig, M. J., Ying, C., & Pienta, K. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042671 · Cited by 569
Shields, J. D., Fleury, M. E., Yong, C., Tomei, A. A., Randolph, G. J., & Swartz, M. A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.020 · Cited by 552
Tumor-Associated Macrophages Press the Angiogenic Switch in Breast Cancer
Lin, E. Y., & Pollard, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0912 · Cited by 463
Zlotnik, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.22024 · Cited by 421
Differential CC chemokine-induced enhancement of T helper cell cytokine production
Karpus, W. J., Lukacs, N. W., Kennedy, K. J., Smith, W. S., Hurst, S. D., & Barrett, T. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.9.4129 · Cited by 413
The chemokine system and cancer
Balkwill, F. R. (2012) · The Journal of Pathology · doi:10.1002/path.3029 · Cited by 412
Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 412
Geminder, H., Sagi-Assif, O., Goldberg, L., Meshel, T., Rechavi, G., Witz, I. P., & Ben-Baruch, A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4747 · Cited by 409
Chun, E., Lavoie, S., Michaud, M., Gallini, C. A., Kim, J., Soucy, G., Odze, R., Glickman, J. N., & Garrett, W. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.024 · Cited by 402 · cited 2×
“Furthermore, CCL2 blocking antibodies decreased tumor and MDSC numbers, suggesting dual functions of CCL2 on both cancer and stromal cells [80].”
BackgroundThe MCP/eotaxin subfamily of CC chemokines
Van Coillie, E., Van Damme, J., & Opdenakker, G. (1999) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(99)00005-2 · Cited by 350
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers
Huang, B., Lei, Z., Zhao, J., Gong, W., Liu, J., Chen, Z., Liu, Y., Li, D., Yuan, Y., Zhang, G.-M., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.012 · Cited by 349
Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., Wojno, K., Snyder, L. A., Yan, L., & Pienta, K. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1286 · Cited by 333
Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1
Goede, V., Brogelli, L., Ziche, M., & Augustin, H. G. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990827)82:5<765::aid-ijc23>3.0.co;2-f · Cited by 319
Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ TH2 cells
Islam, S. A., Chang, D. S., Colvin, R. A., Byrne, M. H., McCully, M. L., Moser, B., Lira, S. A., Charo, I. F., & Luster, A. D. (2011) · Nature Immunology · doi:10.1038/ni.1984 · Cited by 307
Gazzaniga, S., Bravo, A. I., Guglielmotti, A., van Rooijen, N., Maschi, F., Vecchi, A., Mantovani, A., Mordoh, J., & Wainstok, R. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700827 · Cited by 302
Wolf, M. J., Hoos, A., Bauer, J., Boettcher, S., Knust, M., Weber, A., Simonavicius, N., Schneider, C., Lang, M., Stürzl, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.023 · Cited by 290
Saji, H., Koike, M., Yamori, T., Saji, S., Seiki, M., Matsushima, K., & Toi, M. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1085::aid-cncr1424>3.0.co;2-k · Cited by 288
Weber, K. S. C., Nelson, P. J., Gröne, H.-J., & Weber, C. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.9.2085 · Cited by 279
Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 272
Senescent cells develop a parp-1 and nuclear factor-κB-associated secretome (PNAS).
Ohanna, M., Giuliano, S., Bonet, C., Imbert, V., Hofman, V., Zangari, J., Bille, K., Robert, C., Bressac-de Paillerets, B., Hofman, P., et al. (2011) · Genes & Development · doi:10.1101/gad.625811 · Cited by 267
Obesity Promotes Breast Cancer by CCL2-Mediated Macrophage Recruitment and Angiogenesis
Arendt, L. M., McCready, J., Keller, P. J., Baker, D. D., Naber, S. P., Seewaldt, V., & Kuperwasser, C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0926 · Cited by 265
Fujimoto, H., Sangai, T., Ishii, G., Ikehara, A., Nagashima, T., Miyazaki, M., & Ochiai, A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24378 · Cited by 263
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis
Zhang, J., Patel, L., & Pienta, K. J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.009 · Cited by 261
CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and Proliferation
Loberg, R. D., Day, L. L., Harwood, J., Ying, C., St. John, L. N., Giles, R., Neeley, C. K., & Pienta, K. J. (2006) · Neoplasia · doi:10.1593/neo.06280 · Cited by 255
Loberg, R. D., Ying, C., Craig, M., Yan, L., Snyder, L. A., & Pienta, K. J. (2007) · Neoplasia · doi:10.1593/neo.07307 · Cited by 242
Lu, Y., Cai, Z., Galson, D. L., Xiao, G., Liu, Y., George, D. E., Melhem, M. F., Yao, Z., & Zhang, J. (2006) · The Prostate · doi:10.1002/pros.20464 · Cited by 242
Vergunst, C. E., Gerlag, D. M., Lopatinskaya, L., Klareskog, L., Smith, M. D., van den Bosch, F., Dinant, H. J., Lee, Y., Wyant, T., Jacobson, E. W., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23591 · Cited by 236
Torres, S., Bartolomé, R. A., Mendes, M., Barderas, R., Fernandez-Aceñero, M. J., Peláez-García, A., Peña, C., Lopez-Lucendo, M., Villar-Vázquez, R., de Herreros, A. G., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1130 · Cited by 227
Zhao, L., Lim, S. Y., Gordon-Weeks, A. N., Tapmeier, T. T., Im, J. H., Cao, Y., Beech, J., Allen, D., Smart, S., & Muschel, R. J. (2013) · Hepatology · doi:10.1002/hep.26094 · Cited by 225
Self-citationMizutani, K., Sud, S., McGregor, N. A., Martinovski, G., Rice, B. T., Craig, M. J., Varsos, Z. S., Roca, H., & Pienta, K. J. (2009) · Neoplasia · doi:10.1593/neo.09988 · Cited by 220
Brana, I., Calles, A., LoRusso, P. M., Yee, L. K., Puchalski, T. A., Seetharam, S., Zhong, B., de Boer, C. J., Tabernero, J., & Calvo, E. (2015) · Targeted Oncology · doi:10.1007/s11523-014-0320-2 · Cited by 216
Monti, P., Leone, B. E., Marchesi, F., Balzano, G., Zerbi, A., Scaltrini, F., Pasquali, C., Calori, G., Pessi, F., Sperti, C., et al. (2003) · PubMed · Cited by 209
New nomenclature for atypical chemokine receptors
Bachelerie, F., Graham, G. J., Locati, M., Mantovani, A., Murphy, P. M., Nibbs, R., Rot, A., Sozzani, S., & Thelen, M. (2014) · Nature Immunology · doi:10.1038/ni.2812 · Cited by 200
Fang, W. B., Jokar, I., Zou, A., Lambert, D., Dendukuri, P., & Cheng, N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365999 · Cited by 197
Twist1 Induces CCL2 and Recruits Macrophages to Promote Angiogenesis
Low-Marchelli, J. M., Ardi, V. C., Vizcarra, E. A., van Rooijen, N., Quigley, J. P., & Yang, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-0653 · Cited by 190
Recent developments in CCR2 antagonists
Xia, M., & Sui, Z. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902755129 · Cited by 189
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Zhu, X., Fujita, M., Snyder, L. A., & Okada, H. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0473-5 · Cited by 189
Gilbert, J., Lekstrom-Himes, J., Donaldson, D., Lee, Y., Hu, M., Xu, J., Wyant, T., & Davidson, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.005 · Cited by 185
Molecular mechanisms underlying tumor dormancy
Almog, N. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.004 · Cited by 178
CCL2 Regulates Angiogenesis via Activation of Ets-1 Transcription Factor
Stamatovic, S. M., Keep, R. F., Mostarica-Stojkovic, M., & Andjelkovic, A. V. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2651 · Cited by 177
CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases
Craig, M. J., & Loberg, R. D. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9027-x · Cited by 165
Roca, H., Varsos, Z., & Pienta, K. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801073200 · Cited by 163
Oxidative modifications of S100 proteins: functional regulation by redox
Lim, S. Y., Raftery, M. J., Goyette, J., Hsu, K., & Geczy, C. L. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1008608 · Cited by 162
Self-citationTumor‐associated fibroblasts recruit blood monocytes into tumor tissue
Silzle, T., Kreutz, M. P., Dobler, M. A., Brockhoff, G., Knuechel, R., & Kunz‐Schughart, L. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323057 · Cited by 145
Tumor–Microenvironment Interactions: Dangerous Liaisons
Witz, I. P. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00007-9 · Cited by 137
Said, N. A., Sänchez‐Carbayo, M., Smith, S. C., & Theodorescu, D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61392 · Cited by 135
Kuroda, T., Kitadai, Y., Tanaka, S., Yang, X., Mukaida, N., Yoshihara, M., & Chayama, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0798 · Cited by 129
Wong, L.-M., Myers, S. J., Tsou, C.-L., Gosling, J., Arai, H., & Charo, I. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.2.1038 · Cited by 121
Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients
Hefler, L., Tempfer, C., Heinze, G., Mayerhofer, K., Breitenecker, G., Leodolter, S., Reinthaller, A., & Kainz, C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690776 · Cited by 118
Yoshimura, T., Howard, O. M. Z., Ito, T., Kuwabara, M., Matsukawa, A., Chen, K., Liu, Y., Liu, M., Oppenheim, J. J., & Wang, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058791 · Cited by 113
Tang, C., & Tsai, C.-C. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.013 · Cited by 109
A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion
Stathopoulos, G. T., Psallidas, I., Moustaki, A., Moschos, C., Kollintza, A., Karabela, S. P., Porfyridis, I., Vassiliou, S., Karatza, M., Zhou, Z., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn325 · Cited by 105
Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges
Vela, M., Aris, M., Llorente, M., García‐Sanz, J. A., & Kremer, L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00012 · Cited by 102
van Deventer, H. W., Palmieri, D., Wu, Q., McCook, E. C., & Serody, J. S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202857 · Cited by 95
Dagouassat, M., Suffee, N., Hlawaty, H., Haddad, O., Charni, F., Laguillier, C., Vassy, R., Martin, L., Schischmanoff, P. O., Gattegno, L., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24800 · Cited by 93
Zhang, T., Somasundaram, R., Berencsi, K., Caputo, L., Gimotty, P. A., Rani, P., Guerry, D., Swoboda, R., & Herlyn, D. (2006) · European Journal of Immunology · doi:10.1002/eji.200526208 · Cited by 89
Bartoli, C., Civatte, M., Pellissier, J., & Figarella‐Branger, D. (2001) · Acta Neuropathologica · doi:10.1007/s004010100394 · Cited by 84
Hu, H., Sun, L., Guo, C., Liu, Q., Zhou, Z., Peng, L., Pan, J., Yu, L., Lou, J.-N., Yang, Z., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2491 · Cited by 84
Benlimame, N., Alaoui-Jamali, M., & Davis, M. B. (2009) · Cited by 80
Chiu, H.-Y., Sun, K., Chen, S., Wang, H.-H., Lee, M.-Y., Tsou, Y.-C., Jwo, S., Sun, G.-H., & Tang, S. (2012) · Cytokine · doi:10.1016/j.cyto.2012.04.017 · Cited by 71
CCL2 increases αvβ3 integrin expression and subsequently promotes prostate cancer migration
Lin, T., Liu, H.-H., Tsai, T.-H., Chen, C., Hsieh, T., Lee, S., Lee, Y., Chen, W., & Tang, C. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.06.033 · Cited by 66
Lü, Y., Xiao, G., Galson, D. L., Nishio, Y., Mizokami, A., Keller, E. T., Yao, Z., & Zhang, J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22704 · Cited by 65
Sanders, S. K., Crean, S. M., Boxer, P. A., Kellner, D., LaRosa, G. J., & Hunt, S. W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.4877 · Cited by 63
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study
Tsaur, I., Noack, A., Makarević, J., Oppermann, E., Waaga-Gasser, A. M., Gasser, M., Borgmann, H., Hüesch, T., Gust, K. M., Reiter, M., et al. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.015 · Cited by 57
Matsukawa, A., Lukacs, N. W., Standiford, T. J., Chensue, S. W., & Kunkel, S. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1699 · Cited by 56
CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac
van Golen, K. L., Chi, Y., Sequeira, L., et al. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21652 · Cited by 53
Tao, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4421 · Cited by 42
Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888
Obmolova, G., Teplyakov, A., Malia, T., Grygiel, T. L. R., Sweet, R. W., Snyder, L. A., & Gilliland, G. L. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.03.022 · Cited by 37
Profile of Monocyte Chemoattractant Protein-1 Circulating Levels in Gastric Cancer Patients
Tonouchi, H., Miki, C., Tanaka, K., & Kusunoki, M. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/gas.37.7.830.833 · Cited by 36
D6: the ‘crowd controller’ at the immune gateway
Lee, K. M., Nibbs, R. J. B., & Graham, G. J. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.08.001 · Cited by 33
Prioritizing genes associated with prostate cancer development
Gorlov, I. P., Sircar, K., Zhao, H., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-599 · Cited by 33
Futagami, S., Tatsuguchi, A., Hiratsuka, T., Shindo, T., Horie, A., Hamamoto, T., Ueki, N., Kusunoki, M., Miyake, K., Gudis, K., et al. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-007-2151-8 · Cited by 26
Soluble Tumor Necrosis Factor Receptors Shed by Breast Tumor Cells Inhibit Macrophage Chemotaxis
Rego, S. L., Swamydas, M., Kidiyoor, A., Helms, R., Piante, A. D., Lance, A. L., Mukherjee, P., & Dréau, D. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0009 · Cited by 15
Fibroblast-Derived CCL2 Induces Cancer Stem Cells—Response
Tsuyada, A., & Wang, S. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3194 · Cited by 6
Neutralization of CCL2 inhibits tumor angiogenesis and pancreatic tumor growth
Snyder, L. A., Kesavan, P., Kaiser, E., Rudnick, K. A., McCabe, F. J., Millar, H. J., Nakada, M. T., & Li, Y. (2007) · Molecular Cancer Therapeutics · Cited by 4
Moog-Lutz (1997) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0215(19970410)71:2
Cited by
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Pyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
Metadata
- Authors
- Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N., & Muschel, R. J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-02-14
- Volume
- 7
- Issue
- 19
- Pages
- 28697-28710
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2281046076
- Cited by
- 501
- References
- 113
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.